글로벌 저갑상선기능저하증 약물 시장 - 업계 동향 및 2029년까지의 예측

시장 분석 및 통찰력 글로벌 저갑상선기능저하증 약물 시장

저갑상선기능저하증 약물 시장은 2022년에서 2029년의 예측 기간 동안 8.55%의 시장 성장을 목격할 것으로 예상됩니다. 저갑상선기능저하증 약물 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 전 세계적으로 의료 분야의 증가는 저갑상선기능저하증 약물 시장의 성장을 가속화하고 있습니다.

저갑상선기능저하증은 목에 있는 부갑상선에서 부갑상선 호르몬이 부족하게 생성되는 드문 질환을 말합니다. 이 호르몬은 인체의 칼슘과 인산염 수치의 균형을 조절하고 유지하는 데 필수적입니다. 이 질병은 혈액 내 인산염 수치가 높고 칼슘 수치가 낮은 것이 특징입니다.

전 세계적으로 저갑상선기능저하증으로 고통받는 사람들의 증가는 저갑상선기능저하증 약물 시장 성장을 이끄는 주요 요인 중 하나로 작용합니다. 제품 개선을 위한 제약 회사의 연구개발 증가와 갑상선 수술 횟수 증가는 시장 성장을 가속화합니다. 상업적 파이프라인의 개발과 인구 중 암 발생률의 급증은 시장에 더 많은 영향을 미칩니다. 또한, 지원적인 정부 입법, 의료비 지출의 급증, 규제 승인 절차의 단축, 기술 개발 및 기술적 진보는 저갑상선기능저하증 약물 시장에 긍정적인 영향을 미칩니다. 나아가, 새로운 적응증에 대한 연구는 2022년에서 2029년의 예측 기간 동안 시장 참여자에게 수익성 있는 기회를 확대합니다.

On the other hand, introduction of generic drugs and high cost associated with the treatment are expected to obstruct the market growth. The lack of awareness among the patient and physician about hypoparathyroidism treatment are projected to challenge the hypoparathyroidism drug market in the forecast period of 2022-2029.

This hypoparathyroidism drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info hypoparathyroidism drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Hypoparathyroidism Drug Market Scope and Market Size

The hypoparathyroidism drug market is segmented on the basis of type, treatment type, drug type, route of administration and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the hypoparathyroidism drug market is segmented into latrogenic hypoparathyroidism, idiopathic hypoparathyroidism and others. Idiopathic hypoparathyroidism has been further segmented into inherited genetic hypoparathyroidism, pseudo-hypoparathyroidism and autoimmune hypoparathyroidism.
• On the basis of treatment type, the hypoparathyroidism drug market is segmented into medication, dietary supplements, surgery, hormonal therapy and others.
• On the basis of drug type, the hypoparathyroidism drug market is segmented into vitamin D, parathyroid hormone, tricalcium phosphate, calcium lactate, liothyronine, levothyroxine, desiccated thyroid and others.
• On the basis of route of administration, the hypoparathyroidism drug market is segmented into oral and injectable.
• On the basis of end-users, the hypoparathyroidism drug market is segmented into hospitals, homecare, specialty clinics and others.

Hypoparathyroidism Drug Market Country Level Analysis

The hypoparathyroidism drug market is analyzed and market size information is provided by country, type, treatment type, drug type, route of administration and end-users as referenced above.

The countries covered in the global hypoparathyroidism drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the hypoparathyroidism drug market due to the rise in thyroid-related diseases and surge in initiatives by pharmaceutical organizations to generate novel formulations within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the presence of generic manufacturers in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The hypoparathyroidism drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Hypoparathyroidism Drug Market Share Analysis

The hypoparathyroidism drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related hypoparathyroidism drug market.

저갑상선기능저하증 약물 시장의 주요 기업으로는 Teva Pharmaceutical Industries Ltd, EnteraBio Ltd., F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd, Tesaro, Amgen, Inc., Ascendis Pharma A/S 등이 있습니다.

SKU-37167